These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1056 related items for PubMed ID: 32066536

  • 1. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
    Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, Humbert M, Castro M, Marsteller DA, McElhattan J, Hickey L, Garin M, Vanlandingham R, Brusselle G.
    Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
    [Abstract] [Full Text] [Related]

  • 2. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, Eckert L, Graham NM, Stahl N, Yancopoulos GD, Louis-Tisserand M, Teper A.
    Lancet; 2016 Jul 02; 388(10039):31-44. PubMed ID: 27130691
    [Abstract] [Full Text] [Related]

  • 3. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
    Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S.
    Lancet Respir Med; 2015 May 02; 3(5):355-66. PubMed ID: 25736990
    [Abstract] [Full Text] [Related]

  • 4. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG.
    Lancet Respir Med; 2014 Nov 02; 2(11):879-890. PubMed ID: 25306557
    [Abstract] [Full Text] [Related]

  • 5. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID.
    Lancet Respir Med; 2016 Jul 02; 4(7):549-556. PubMed ID: 27177493
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
    Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators.
    Lancet; 2016 Oct 29; 388(10056):2115-2127. PubMed ID: 27609408
    [Abstract] [Full Text] [Related]

  • 7. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M, CALIMA study investigators.
    Lancet; 2016 Oct 29; 388(10056):2128-2141. PubMed ID: 27609406
    [Abstract] [Full Text] [Related]

  • 8. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M, BISE Study Investigators.
    Lancet Respir Med; 2017 Jul 29; 5(7):568-576. PubMed ID: 28545978
    [Abstract] [Full Text] [Related]

  • 9. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG, ANDHI study investigators.
    Lancet Respir Med; 2021 Mar 29; 9(3):260-274. PubMed ID: 33357499
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE, Chanez P, Leigh R, O'Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E.
    Lancet Respir Med; 2015 Sep 29; 3(9):692-701. PubMed ID: 26231288
    [Abstract] [Full Text] [Related]

  • 11. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
    FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M.
    Lancet Respir Med; 2018 Jan 29; 6(1):51-64. PubMed ID: 28919200
    [Abstract] [Full Text] [Related]

  • 12. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
    Corren J, Weinstein S, Janka L, Zangrilli J, Garin M.
    Chest; 2016 Oct 29; 150(4):799-810. PubMed ID: 27018175
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
    Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG.
    Lancet Respir Med; 2016 Oct 29; 4(10):781-796. PubMed ID: 27616196
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study.
    Wechsler ME, Menzies-Gow A, Brightling CE, Kuna P, Korn S, Welte T, Griffiths JM, Sałapa K, Hellqvist Å, Almqvist G, Lal H, Kaur P, Skärby T, Colice G, SOURCE study group.
    Lancet Respir Med; 2022 Jul 29; 10(7):650-660. PubMed ID: 35364018
    [Abstract] [Full Text] [Related]

  • 15. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
    Mukherjee M, Aleman Paramo F, Kjarsgaard M, Salter B, Nair G, LaVigne N, Radford K, Sehmi R, Nair P.
    Am J Respir Crit Care Med; 2018 Jan 01; 197(1):38-46. PubMed ID: 28915080
    [Abstract] [Full Text] [Related]

  • 16. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E.
    Adv Ther; 2020 Feb 01; 37(2):718-729. PubMed ID: 31836949
    [Abstract] [Full Text] [Related]

  • 17. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
    Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X.
    Curr Med Res Opin; 2017 Sep 01; 33(9):1605-1613. PubMed ID: 28644104
    [Abstract] [Full Text] [Related]

  • 18. Omalizumab for asthma in adults and children.
    Normansell R, Walker S, Milan SJ, Walters EH, Nair P.
    Cochrane Database Syst Rev; 2014 Jan 13; 2014(1):CD003559. PubMed ID: 24414989
    [Abstract] [Full Text] [Related]

  • 19. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
    Brightling CE, Bleecker ER, Panettieri RA, Bafadhel M, She D, Ward CK, Xu X, Birrell C, van der Merwe R.
    Lancet Respir Med; 2014 Nov 13; 2(11):891-901. PubMed ID: 25208464
    [Abstract] [Full Text] [Related]

  • 20. Anti-IL5 therapies for asthma.
    Farne HA, Wilson A, Powell C, Bax L, Milan SJ.
    Cochrane Database Syst Rev; 2017 Sep 21; 9(9):CD010834. PubMed ID: 28933516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.